肩峰下撞击症候群市场 - 全球产业规模、份额、趋势、机会及预测（按肌肉骨骼疾病类型、诊断和影像技术、治疗方法、最终用户、地区和竞争格局划分，2021-2031年）

全球肩峰下撞击症候群市场预计将从 2025 年的 87.2 亿美元成长到 2031 年的 134.1 亿美元，复合年增长率为 7.44%。

肩峰撞击症候群是指肩关节内的滑囊或肌腱受到压迫的一种疾病，其治疗方法多种多样，从药物和物理治疗等保守治疗到关节镜减压手术均有涵盖。市场成长的主要驱动因素是老年人口的增加（老年人更容易患退化性结缔组织疾病）以及因重复性过顶运动导致的运动伤害增加。这些关键因素正在持续推动对有效疼痛管理策略和旨在恢復患者功能性活动能力的整形外科解决方案的需求。

然而，由于择期关节镜手术费用高昂，以及可能限制患者获得先进治疗的报销政策，市场成长面临潜在障碍。此外，长期药物治疗的副作用也会使患者难以坚持保守治疗方案。美国整形外科学会报告称，2024年，该学会登记的肩迴旋肌手术中，有59%同时进行了肩峰下减压手术，显示该疾病的临床病例量巨大。

市场驱动因素

全球肩迴旋肌损伤和肩峰撞击症候群的发生率不断上升，这主要受人口快速老化的影响，也是推动市场扩张的主要因素。随着老龄人口的增长，需要医疗干预的退化性结缔组织疾病也随之增加；同时，更年轻、更活跃的人群也面临着因高举过头运动而导致的重复性劳损的日益普遍。这两类患者的涌入持续推高了对整形外科修復解决方案的需求，直接提升了医疗设备製造商的收入。史赛克公司在2025年10月举行的「2025年第三季财报电话会议」中重点强调了这一趋势。该公司宣布，其整形外科部门实现了11.4%的内部成长，并将这一成功主要归功于肩部护理产品的持续增长势头以及门诊手术中心手术量的增加。

同时，微创关节关节镜手术技术的进步正在改善临床疗效并扩大潜在患者群。符合人体工学的动力器械、无结固定装置和高清可视化技术的创新，使外科医生能够以更小的组织损伤进行精准的肩峰下减压手术，从而加快患者康復。这些进步不仅提高了手术效率，也缩短了手术器械的更换週期。例如，在2025年6月题为「Arthrex推出革命性动力器材系统」的新闻稿中，Arthrex宣布推出其Synergy动力系统，该系统增强了先进的关节置换和运动医学技术。此类技术应用带来的商业性影响在整个产业中显而易见，CONMED在2025年11月发布的报告显示，得益于强大的外科产品组合，其第三季销售额年增6.7%至3.379亿美元。

市场挑战

严格的健保报销政策和高昂的择期关节镜手术费用严重阻碍了肩峰撞击症候群市场的发展。由于先进的手术治疗缺乏足够的健保覆盖，患者往往需要承担高额的自付费用，从而放弃或延后手术减压。这种经济负担直接减少了手术介入的数量，并促使市场倾向于盈利较低的保守治疗方法。这反过来又抑制了专用手术器械和相关整形外科解决方案的应用，从而限制了该行业的潜在成长。

此外，主要支付方报销率的下降给医疗服务提供者造成了不可持续的经济环境，使他们无法优先考虑这些择期手术。据美国整形外科医师协会称，2024年实施的联邦医疗保险医师收费标准将转换係数降低了约3.4%，进一步压缩了整形外科诊所的营运利润。报销奖励的持续减少迫使医疗机构整合服务或限制资源密集型肩峰下撞击症候群手术方案的提供，阻碍了整体市场成长。

市场趋势

生物诱导支架在肌腱修復中的日益广泛应用，正从根本上改变治疗通讯协定，因为它解决了肩迴旋肌手术中机械固定的生物学限制。与仅依赖组织对合的传统缝合技术不同，这些生物诱导植入能够促进自然癒合并增加肌腱厚度，从而降低因组织退化而导致的再次断裂的高风险。这项临床优势促使其迅速商业性化，外科医师越来越多地采用这些生物材料来加强结缔组织薄弱患者的修復，并将其作为关节镜减压手术的辅助手段。例如，史密斯-内普公司在其2025年8月发布的「2025财年第二季/上半年收益报告」中指出，其REGENETEN生物诱导植入的销售额实现了两位数的强劲增长，这凸显了运动医学领域向生物强化疗法的加速转变。

同时，随着医疗机构更加重视多模式镇痛方法，旨在促进患者康復并减少阿片类药物依赖，非阿片类术后镇痛通讯协定的发展势头强劲。这一趋势对于门诊进行的肩峰下撞击综合征手术尤其重要，因为长效局部麻醉剂能够帮助患者早期活动和出院，且不会产生与麻醉性镇痛药相关的全身性副作用。市场上，缓释脂质体Bupivacaine製剂的使用日益增多，这类製剂能够直接在手术部位提供持续镇痛，进而提高病患满意度。为了佐证这一转变，Pasira Biosciences公司于2025年11月宣布，其产品EXPAREL的净销售额达到1.399亿美元，这主要得益于9%的销量增长，也反映了非阿片类术后镇痛治疗标准的不断演进。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球肩峰下撞击症候群市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依肌肉骨骼疾病类型（骨关节炎、类风湿性关节炎、骨质疏鬆症、背部和颈部疼痛、肩峰撞击症候群、膝关节疼痛和疾病、髋关节疼痛和疾病、创伤和骨折、运动伤害、其他）
  • 透过诊断和影像技术（X光、磁振造影（MRI）、电脑断层扫描（CT）、超音波、关节镜检查、其他）
  • 依治疗方法（药物治疗、手术介入）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美肩峰下撞击症候群市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲肩峰下撞击症候群市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区肩周炎市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲肩峰下撞击症候群市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲肩峰撞击症候群市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球肩峰下撞击症候群市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bioventus LLC
• Orthofix Medical Inc.
• Breg, Inc.
• ConMed Corporation
• Ossur hf.
• Arthrex, Inc.
• Globus Medical, Inc.
• NuVasive, Inc.
• Stryker Corporation
• Medtronic plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Impingement Syndrome Market is projected to expand from a valuation of USD 8.72 Billion in 2025 to USD 13.41 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.44%. Defined as a pathological condition involving the compression of bursa or tendons within the shoulder joint, impingement syndrome necessitates treatments ranging from conservative measures like pharmaceuticals and physical therapy to arthroscopic surgical decompression. The market's growth is largely fueled by a growing elderly demographic prone to degenerative connective tissue issues and an increase in sports-related injuries resulting from repetitive overhead actions. These core drivers generate consistent demand for effective pain management strategies and orthopedic solutions aimed at restoring functional mobility in affected individuals.

Conversely, market growth faces potential hurdles due to the significant expenses linked to elective arthroscopic surgeries and restrictive reimbursement policies that may curtail patient access to advanced procedural care. Furthermore, adherence to conservative treatment plans can be compromised by the adverse effects associated with long-term medication use. Highlighting the substantial clinical volume of this condition, the American Academy of Orthopaedic Surgeons reported in 2024 that 59% of rotator cuff procedures entered into their registry involved concurrent subacromial decompression.

Market Driver

The escalating global incidence of rotator cuff disorders and shoulder impingement, significantly intensified by a rapidly aging population, acts as the primary catalyst for market expansion. As the elderly demographic grows, there is a parallel rise in degenerative connective tissue diseases requiring medical attention, while younger, active individuals increasingly suffer from repetitive strain injuries due to overhead sports. This twofold patient influx generates continuous demand for orthopedic repair solutions, directly enhancing revenue for medical device companies. This trend was illustrated by Stryker during their 'Q3 2025 Earnings Call' in October 2025, where the company announced that its orthopedics division attained 11.4% organic growth, a success largely ascribed to sustained momentum in shoulder care offerings and rising procedure volumes in ambulatory surgery centers.

Concurrently, technological progress in minimally invasive arthroscopic techniques is improving clinical results and widening the potential patient base. The innovation of ergonomic power instruments, knotless fixation devices, and high-definition visualization allows surgeons to execute precise subacromial decompressions with reduced tissue disruption, thereby hastening patient recovery. These advancements not only enhance procedural effectiveness but also stimulate the replacement cycle for surgical tools. For instance, in a June 2025 press release titled 'Arthrex Introduces Innovative Powered Instrument System', Arthrex debuted the Synergy Power System to bolster advanced arthroplasty and sports medicine techniques. The commercial influence of adopting such technology is apparent industry-wide; CONMED Corporation reported in November 2025 that it secured third-quarter sales of $337.9 million, marking a 6.7% year-over-year rise driven by its robust surgical portfolio.

Market Challenge

Restrictive reimbursement policies and the high costs attached to elective arthroscopic surgeries represent considerable obstacles to the growth of the impingement syndrome market. When financial coverage for advanced procedural care is constrained, patients encounter significant out-of-pocket costs, often leading them to decline or postpone surgical decompression. This lack of economic accessibility directly lowers the volume of surgical interventions, shifting market preference toward conservative, lower-cost therapies that yield lower revenue. As a result, the uptake of specialized surgical devices and related orthopedic solutions is suppressed, curbing the sector's potential financial expansion.

Moreover, decreasing reimbursement rates from major payers establish an unsustainable economic landscape for healthcare providers, dissuading the prioritization of these elective surgeries. According to the American Academy of Orthopaedic Surgeons, the 2024 implementation of the Medicare Physician Fee Schedule led to a conversion factor reduction of approximately 3.4 percent, which further squeezed operating margins for orthopedic practices. This ongoing reduction of reimbursement incentives compels medical facilities to consolidate services or restrict the availability of resource-heavy surgical options for impingement syndrome, thereby inhibiting the overall market trajectory.

Market Trends

The increasing use of bio-inductive scaffolds for tendon repair is fundamentally transforming treatment protocols by targeting the biological constraints of mechanical fixation in rotator cuff procedures. In contrast to conventional suture-only methods that depend solely on tissue approximation, these bio-inductive implants encourage natural healing and enhance tendon thickness, thereby alleviating the high re-tear risk linked to degenerative tissue quality. This clinical benefit is propelling rapid commercial adoption as surgeons increasingly employ these biologics to reinforce repairs and augment arthroscopic decompressions in patients with weak connective tissue. Highlighting this demand, Smith+Nephew reported in their 'Second Quarter and First Half 2025 Results' in August 2025 that they achieved strong double-digit revenue growth from their REGENETEN Bioinductive Implant, underscoring the accelerating transition toward biological augmentation in sports medicine.

Simultaneously, the advancement of non-opioid post-operative pain management protocols is gathering momentum as healthcare providers focus on multimodal analgesia to support recovery and reduce opioid reliance. This trend is especially pertinent for impingement syndrome surgeries conducted in outpatient settings, where long-acting local anesthetics facilitate earlier mobilization and discharge without the systemic side effects associated with narcotics. The market is observing rising usage of extended-release liposomal bupivacaine formulations that offer sustained pain relief directly at the surgical site, thereby boosting patient satisfaction scores. Demonstrating this shift, Pacira BioSciences announced in November 2025, within their 'Pacira BioSciences Reports Third Quarter 2025 Financial Results', that the company realized net product sales of $139.9 million for EXPAREL, driven by a 9% volume increase that reflects the evolving standard of care for non-opioid postsurgical pain control.

Key Market Players

• Bioventus LLC
• Orthofix Medical Inc.
• Breg, Inc.
• ConMed Corporation
• Ossur hf.
• Arthrex, Inc.
• Globus Medical, Inc.
• NuVasive, Inc.
• Stryker Corporation
• Medtronic plc

Report Scope

In this report, the Global Impingement Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Impingement Syndrome Market, By Type of Musculoskeletal Disorder

• Osteoarthritis
• Rheumatoid Arthritis
• Osteoporosis
• Back and Neck Pain
• Shoulder Impingement Syndrome
• Knee Pain and Disorders
• Hip Pain and Disorders
• Trauma and Fracture
• Sports Injuries
• Others

Impingement Syndrome Market, By Diagnosis and Imaging Techniques

• X-ray
• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT) Scan
• Ultrasound
• Arthroscopy
• Others

Impingement Syndrome Market, By Treatment Modalities

• Medications
• Surgical Interventions

Impingement Syndrome Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Impingement Syndrome Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Impingement Syndrome Market.

Available Customizations:

Global Impingement Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Impingement Syndrome Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Musculoskeletal Disorder (Osteoarthritis, Rheumatoid Arthritis, Osteoporosis, Back and Neck Pain, Shoulder Impingement Syndrome, Knee Pain and Disorders, Hip Pain and Disorders, Trauma and Fracture, Sports Injuries, Others)
  • 5.2.2. By Diagnosis and Imaging Techniques (X-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Ultrasound, Arthroscopy, Others)
  • 5.2.3. By Treatment Modalities (Medications, Surgical Interventions)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Impingement Syndrome Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Musculoskeletal Disorder
  • 6.2.2. By Diagnosis and Imaging Techniques
  • 6.2.3. By Treatment Modalities
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Impingement Syndrome Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Musculoskeletal Disorder
      • 6.3.1.2.2. By Diagnosis and Imaging Techniques
      • 6.3.1.2.3. By Treatment Modalities
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Impingement Syndrome Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Musculoskeletal Disorder
      • 6.3.2.2.2. By Diagnosis and Imaging Techniques
      • 6.3.2.2.3. By Treatment Modalities
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Impingement Syndrome Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Musculoskeletal Disorder
      • 6.3.3.2.2. By Diagnosis and Imaging Techniques
      • 6.3.3.2.3. By Treatment Modalities
      • 6.3.3.2.4. By End User

7. Europe Impingement Syndrome Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Musculoskeletal Disorder
  • 7.2.2. By Diagnosis and Imaging Techniques
  • 7.2.3. By Treatment Modalities
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Impingement Syndrome Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Musculoskeletal Disorder
      • 7.3.1.2.2. By Diagnosis and Imaging Techniques
      • 7.3.1.2.3. By Treatment Modalities
      • 7.3.1.2.4. By End User
  • 7.3.2. France Impingement Syndrome Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Musculoskeletal Disorder
      • 7.3.2.2.2. By Diagnosis and Imaging Techniques
      • 7.3.2.2.3. By Treatment Modalities
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Impingement Syndrome Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Musculoskeletal Disorder
      • 7.3.3.2.2. By Diagnosis and Imaging Techniques
      • 7.3.3.2.3. By Treatment Modalities
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Impingement Syndrome Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Musculoskeletal Disorder
      • 7.3.4.2.2. By Diagnosis and Imaging Techniques
      • 7.3.4.2.3. By Treatment Modalities
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Impingement Syndrome Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Musculoskeletal Disorder
      • 7.3.5.2.2. By Diagnosis and Imaging Techniques
      • 7.3.5.2.3. By Treatment Modalities
      • 7.3.5.2.4. By End User

8. Asia Pacific Impingement Syndrome Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Musculoskeletal Disorder
  • 8.2.2. By Diagnosis and Imaging Techniques
  • 8.2.3. By Treatment Modalities
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Impingement Syndrome Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Musculoskeletal Disorder
      • 8.3.1.2.2. By Diagnosis and Imaging Techniques
      • 8.3.1.2.3. By Treatment Modalities
      • 8.3.1.2.4. By End User
  • 8.3.2. India Impingement Syndrome Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Musculoskeletal Disorder
      • 8.3.2.2.2. By Diagnosis and Imaging Techniques
      • 8.3.2.2.3. By Treatment Modalities
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Impingement Syndrome Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Musculoskeletal Disorder
      • 8.3.3.2.2. By Diagnosis and Imaging Techniques
      • 8.3.3.2.3. By Treatment Modalities
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Impingement Syndrome Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Musculoskeletal Disorder
      • 8.3.4.2.2. By Diagnosis and Imaging Techniques
      • 8.3.4.2.3. By Treatment Modalities
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Impingement Syndrome Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Musculoskeletal Disorder
      • 8.3.5.2.2. By Diagnosis and Imaging Techniques
      • 8.3.5.2.3. By Treatment Modalities
      • 8.3.5.2.4. By End User

9. Middle East & Africa Impingement Syndrome Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Musculoskeletal Disorder
  • 9.2.2. By Diagnosis and Imaging Techniques
  • 9.2.3. By Treatment Modalities
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Impingement Syndrome Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Musculoskeletal Disorder
      • 9.3.1.2.2. By Diagnosis and Imaging Techniques
      • 9.3.1.2.3. By Treatment Modalities
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Impingement Syndrome Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Musculoskeletal Disorder
      • 9.3.2.2.2. By Diagnosis and Imaging Techniques
      • 9.3.2.2.3. By Treatment Modalities
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Impingement Syndrome Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Musculoskeletal Disorder
      • 9.3.3.2.2. By Diagnosis and Imaging Techniques
      • 9.3.3.2.3. By Treatment Modalities
      • 9.3.3.2.4. By End User

10. South America Impingement Syndrome Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Musculoskeletal Disorder
  • 10.2.2. By Diagnosis and Imaging Techniques
  • 10.2.3. By Treatment Modalities
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Impingement Syndrome Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Musculoskeletal Disorder
      • 10.3.1.2.2. By Diagnosis and Imaging Techniques
      • 10.3.1.2.3. By Treatment Modalities
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Impingement Syndrome Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Musculoskeletal Disorder
      • 10.3.2.2.2. By Diagnosis and Imaging Techniques
      • 10.3.2.2.3. By Treatment Modalities
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Impingement Syndrome Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Musculoskeletal Disorder
      • 10.3.3.2.2. By Diagnosis and Imaging Techniques
      • 10.3.3.2.3. By Treatment Modalities
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Impingement Syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bioventus LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Orthofix Medical Inc.
• 15.3. Breg, Inc.
• 15.4. ConMed Corporation
• 15.5. Ossur hf.
• 15.6. Arthrex, Inc.
• 15.7. Globus Medical, Inc.
• 15.8. NuVasive, Inc.
• 15.9. Stryker Corporation
• 15.10. Medtronic plc

16. Strategic Recommendations

17. About Us & Disclaimer